Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPIX NASDAQ:FWP NASDAQ:LIXT NASDAQ:RGLS NASDAQ:SNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPIXCumberland Pharmaceuticals$3.24+0.3%$3.37$1.04▼$7.25$48.46M-0.37589,077 shs379 shsFWPForward Pharma A/S$1.95$2.17$1.50▼$6.48$13.83M1.387,484 shsN/ALIXTLixte Biotechnology$5.54+2.2%$4.36$0.64▼$6.26$25.40M0.46767,713 shs11,575 shsRGLSRegulus Therapeutics$8.16$8.10$0.83▼$8.35$564.92M0.351.02 million shsN/ASNGXSoligenix$1.86-20.1%$2.60$1.09▼$6.23$8.60M2.054.01 million shs5.34 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPIXCumberland Pharmaceuticals+2.54%-4.44%-1.82%-2.12%+164.75%FWPForward Pharma A/S0.00%0.00%0.00%0.00%0.00%LIXTLixte Biotechnology-0.55%-4.91%+58.94%+523.71%+188.30%RGLSRegulus Therapeutics0.00%0.00%0.00%0.00%+348.35%SNGXSoligenix-13.38%-15.27%-31.07%+75.19%-39.01%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPIXCumberland Pharmaceuticals$3.24+0.3%$3.37$1.04▼$7.25$48.46M-0.37589,077 shs379 shsFWPForward Pharma A/S$1.95$2.17$1.50▼$6.48$13.83M1.387,484 shsN/ALIXTLixte Biotechnology$5.54+2.2%$4.36$0.64▼$6.26$25.40M0.46767,713 shs11,575 shsRGLSRegulus Therapeutics$8.16$8.10$0.83▼$8.35$564.92M0.351.02 million shsN/ASNGXSoligenix$1.86-20.1%$2.60$1.09▼$6.23$8.60M2.054.01 million shs5.34 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPIXCumberland Pharmaceuticals+2.54%-4.44%-1.82%-2.12%+164.75%FWPForward Pharma A/S0.00%0.00%0.00%0.00%0.00%LIXTLixte Biotechnology-0.55%-4.91%+58.94%+523.71%+188.30%RGLSRegulus Therapeutics0.00%0.00%0.00%0.00%+348.35%SNGXSoligenix-13.38%-15.27%-31.07%+75.19%-39.01%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPIXCumberland Pharmaceuticals 0.00N/AN/AN/AFWPForward Pharma A/S 0.00N/AN/AN/ALIXTLixte Biotechnology 0.00N/AN/AN/ARGLSRegulus Therapeutics 2.17Hold$8.807.84% UpsideSNGXSoligenix 3.00Buy$6.00222.23% UpsideCurrent Analyst Ratings BreakdownLatest SNGX, FWP, CPIX, RGLS, and LIXT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025SNGXSoligenixAlliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $6.00(Data available from 9/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPIXCumberland Pharmaceuticals$37.87M1.28$0.26 per share12.25$1.61 per share2.01FWPForward Pharma A/SN/AN/AN/AN/A$10.09 per shareN/ALIXTLixte BiotechnologyN/AN/AN/AN/A($1.19) per shareN/ARGLSRegulus TherapeuticsN/AN/AN/AN/A$1.17 per shareN/ASNGXSoligenix$120K66.57N/AN/A$1.64 per share1.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPIXCumberland Pharmaceuticals-$6.48M-$0.22N/A∞N/A-6.97%7.48%2.66%11/6/2025 (Estimated)FWPForward Pharma A/S-$1.89MN/A0.00∞N/AN/AN/AN/AN/ALIXTLixte Biotechnology-$3.59M-$1.29N/A∞N/AN/AN/A-222.90%11/11/2025 (Estimated)RGLSRegulus Therapeutics-$46.36M-$0.73N/AN/AN/AN/A-57.53%-53.26%N/ASNGXSoligenix-$8.27M-$3.80N/AN/AN/AN/A-274.76%-129.20%11/14/2025 (Estimated)Latest SNGX, FWP, CPIX, RGLS, and LIXT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025SNGXSoligenix-$0.79-$0.82-$0.03-$0.82N/AN/A8/7/2025Q2 2025LIXTLixte BiotechnologyN/A-$0.29N/A-$0.29N/AN/A8/5/2025Q2 2025CPIXCumberland PharmaceuticalsN/A$0.02N/A-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPIXCumberland PharmaceuticalsN/AN/AN/AN/AN/AFWPForward Pharma A/SN/AN/AN/AN/AN/ALIXTLixte BiotechnologyN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/ASNGXSoligenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPIXCumberland Pharmaceuticals0.191.301.17FWPForward Pharma A/SN/A18.43N/ALIXTLixte BiotechnologyN/A1.841.84RGLSRegulus TherapeuticsN/A16.3116.31SNGXSoligenixN/A1.471.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPIXCumberland Pharmaceuticals15.51%FWPForward Pharma A/S12.57%LIXTLixte Biotechnology5.10%RGLSRegulus Therapeutics92.38%SNGXSoligenix3.60%Insider OwnershipCompanyInsider OwnershipCPIXCumberland Pharmaceuticals44.85%FWPForward Pharma A/S71.47%LIXTLixte Biotechnology14.80%RGLSRegulus Therapeutics4.35%SNGXSoligenix3.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPIXCumberland Pharmaceuticals8014.96 million8.25 millionOptionableFWPForward Pharma A/S47.09 million2.02 millionNot OptionableLIXTLixte Biotechnology44.56 million3.89 millionNot OptionableRGLSRegulus Therapeutics3069.23 million66.22 millionOptionableSNGXSoligenix204.29 million4.16 millionNot OptionableSNGX, FWP, CPIX, RGLS, and LIXT HeadlinesRecent News About These CompaniesSoligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor4 hours ago | prnewswire.comSoligenix files to sell 2.91M shares of common stock, 2.91M warrantsSeptember 19, 2025 | msn.comSoligenix Tumbles After Company Publishes PaperSeptember 4, 2025 | baystreet.caSoligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related VirusesSeptember 4, 2025 | prnewswire.comSoligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | prnewswire.comSoligenix Inc. Reports Q2 2025 Earnings LossAugust 22, 2025 | msn.comCompanies Like Soligenix (NASDAQ:SNGX) Could Be Quite RiskyAugust 21, 2025 | finance.yahoo.comWhy Is Soligenix Stock Soaring On Monday?August 18, 2025 | benzinga.comSoligenix’s dusquetide granted Orphan Drug Designation in Behcet’s DiseaseAugust 18, 2025 | msn.comSoligenix Shares Surge After FDA Grants Orphan Drug StatusAugust 18, 2025 | msn.comSoligenix stock soars after FDA grants orphan drug designationAugust 18, 2025 | za.investing.comFDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study ResultsAugust 18, 2025 | prnewswire.comSoligenix Faces Nasdaq Non-Compliance NoticeAugust 16, 2025 | msn.comSOLIGENIX, INC.: Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial ResultsAugust 14, 2025 | finanznachrichten.deSoligenix receives FDA orphan designation for dusquetideAugust 14, 2025 | msn.comSoligenix Announces Recent Accomplishments And Second Quarter 2025 Financial ResultsAugust 14, 2025 | prnewswire.comSoligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL TherapyAugust 8, 2025 | finance.yahoo.comNetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin CancerAugust 8, 2025 | globenewswire.comSoligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL ...August 7, 2025 | gurufocus.comSoligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL ...August 7, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNGX, FWP, CPIX, RGLS, and LIXT Company DescriptionsCumberland Pharmaceuticals NASDAQ:CPIX$3.24 +0.01 (+0.28%) As of 10:16 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.Forward Pharma A/S NASDAQ:FWPForward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.Lixte Biotechnology NASDAQ:LIXT$5.54 +0.12 (+2.21%) As of 10:27 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.Regulus Therapeutics NASDAQ:RGLSRegulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.Soligenix NASDAQ:SNGX$1.86 -0.47 (-20.09%) As of 10:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 High-Yields at 52-Week Lows: Buy, Sell, or Hold Advance Auto Parts is A Great Risk/Reward Play If EPS Delivers 3 Small Caps That Insiders Are Buying Amprius Technologies: Anatomy of a Textbook, Raging Bull Market Banks Boost Gold Forecasts: One Sees +30% Bull-Case Potential These 3 Stocks Boosting Buybacks Have Rallying Potential GameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound? Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
